Benitec Limited (ASX:BLT) To Raise A$5.1M Through Proposed Underwritten Non-Renounceable Rights Issue

Friday May 16 4:33 PM

Melbourne, Australia, May 16, 2008 - (ABN Newswire) - The Directors of Benitec Limited (ASX: BLT.AX)(PINK: BNIKF) today announced that the Company proposes to raise approx $5.1 million (before expenses to the offer) by undertaking a fully underwritten non-renounceable rights issue.

It is expected that shareholders will be offered one share at $0.10 cents and a free option for every 5.7 shares held at a record date which will be advised in a subsequent announcement.

The funds to be raised will provide working capital to be applied to the following:

�� Intellectual property prosecution and maintenance including continuing activities with the US patent re-examination. Benitec has a substantial patent estate of 98 patents and patent applications in the RNAi area. Benitec will continue to review options for in-licensing and outlicensing of this estate;

�� Support of the two City of Hope collaboration programs including the human trial for the stem cell HIV lymphoma project and the filing of an IND and commencement of human trials for the T cell HIV project;

�� Support of the Benitec proprietary R&D program including further evaluation of the Hepatitis B, Huntington disease and cancer projects; and

�� Support of operations and ongoing corporate communication to support business development and licensing activities.

The Company are in the process of finalising the agreement with the underwriter who has indicated that they will fully underwrite the issue.

A prospectus containing full details of the proposed rights issue is currently being prepared and the Company expects to lodge it with ASIC and ASX within the next week.

About BENITEC LIMITED:

Benitec is an Australian biotechnology company focused on licensing its extensive intellectual property portfolio and developing therapeutics to treat serious diseases using its proprietary ddRNAi technology. Its current therapeutic program is focused on Human Immunodeficiency Virus (HIV). For additional information, please visit www.benitec.com

Contact:
Sue MacLeman 
Chief Executive Officer 
TEL: +61 437 211 200

Rudi Michelson
Monsoon Communications
TEL: +61 411 402 737
 


Source:

BENITEC LIMITED

Copyright (C) 2008 ABN Newswire. All rights reserved.
ABN Newswire

All Stories


Related Quotes
chart All Detailed Quotes
Delayed 20 mins
Quote data provided by Reuters
Top Stories
· Mosaic Oil (ASX:MOS) Weekly Operations Update - Waggamba-4H Surat-Bowen Basin, Qld. 20080520 - ABN Newswire, ( Tuesday May 20, 2008, 11:04 am)
· Macquarie Group annual profit up 23% - AAP, ( Tuesday May 20, 2008, 11:01 am)
· NAB still mulling St George bid - AAP, ( Tuesday May 20, 2008, 11:00 am)
· Village buys Aussie World in Qld - AAP, ( Tuesday May 20, 2008, 10:57 am)
More...

Finance Message Boards
Most recent posts:
Send Out Cards now in Australia/NZealand19
Gold and Silver180
OZL.....OZ MINERALS221
Geodynamics (GDY)69
Coal to Gas167
More Finance Boards

Email this Article Email this story - Print this Article  Printer friendly version

Next article:Tamaya Resources Limited (ASX:TMR) Shareholder Advisory Line For Share Purchase Plan: Closing 5.00pm EST 26 May 2008
Previous article:CityView Corporation Limited (ASX:CVI) Concludes US$1.1 Billion Project Funding Plans



Copyright © 2008 Yahoo!7 Pty Limited. All rights reserved.
Advertise with Us - Privacy Policy - Terms of Service.